Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.

Authors:

Jiang S, Terasawa E, Horton V, et al.

Year

2020

Conference

ASCO Annual Meeting

Location

Virtual

Start Date

May 29

End Date

Jun 2